---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-003290"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:23:28.138104+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences reports $108.5M preliminary cash; receives $2.5M from TG Therapeutics, issues shares

## Summary
- Preliminary unaudited cash, cash equivalents, and restricted cash of ~$108.5M as of Dec 31, 2024, before $2.5M TG payment in Jan 2025.
- Expects cash runway into second half of 2026, sufficient to fund two wholly owned programs through Phase 1 data readouts.
- On Jan 6, 2025, received $2.5M deferred cash payment from TG Subsidiary and issued 220,712 shares of common stock.
- The payment and shares relate to the January 2024 License Agreement for non-oncology applications of allogeneic CAR T therapy azer-cel.
- These estimates are preliminary and subject to audit.

## SEC filing metadata
- accession: 0000950170-25-003290
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017025003290/0000950170-25-003290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017025003290/dtil-20250106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-003290
- JSON: https://secwatch.observer/filing/0000950170-25-003290.json
- Plain text: https://secwatch.observer/filing/0000950170-25-003290.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.